Erich Seifritz
Director of the Clinic for Affective Disorders at the University of Zurich
Data updated
Research Footprint
Erich Seifritz appears in 28 tracked papers (2012–2026), most studied alongside Psilocybin, Placebo and LSD, across Healthy Volunteers, Neuroimaging & Brain Measures and Depressive Disorders.
Most-cited paper: Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor (408 citations).
Frequent co-authors: Franz Vollenweider, Katrin Preller and Rafael Kraehenmann.
Publication Landscape
How the 28 papers Blossom tracks for Erich Seifritz line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Erich Seifritz's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 28 of 28 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Erich Seifritz publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Erich Seifritz publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Erich Seifritz is a full professor of psychiatry and a leading expert in affective disorders. His research investigates functional brain connectivity and the neurobiology of major depression and schizophrenia. In the psychedelic field, he focuses on psilocybin-assisted therapy and its potential to enhance therapeutic outcomes when combined with psychological frameworks and mindfulness practices.
Key Impact
Prominent psychiatrist exploring the synergy between mindfulness and psilocybin for depression.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Erich Seifritz's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Erich Seifritz is associated with.